Meta threatened with injunction over data-use for AI training
Austrian advocacy group NOYB will seek an injunction against Meta Platforms, it said on Wednesday, that could lead to substantial claims if the tech giant goes ahead with plans to use Europeans' personal data to train its AI models.
NOYB, or none of your business, led by privacy activist Max Schrems, said it had sent a cease and desist letter on Wednesday to Meta, which plans to start using personal data from European users of Instagram and Facebook from May 27.
Meta has cited legitimate interest under EU privacy rules for using users' data to train and develop its generative AI models and other AI tools that can be shared with third parties.
The U.S. tech giant said last month users would receive a link to a form that allows them to object to their data being used for training purposes and that private messages and public data from accounts of users under the age of 18 will not be used.
Schrems criticised Meta's rationale.
"The European Court of Justice has already held that Meta cannot claim a 'legitimate interest' in targeting users with advertising. How should it have a 'legitimate interest' to suck up all data for AI training?" he said in a statement.
"We are currently evaluating our options to file injunctions, but there is also the option for a subsequent class action for non-material damages. If you think about the more than 400 million European Meta users who could all demand damages of just 500 euros or so, you can do the math," Schrems said.
NOYB said an injunction could be filed under the EU Collective Redress, which enables consumers to pursue collective lawsuits against companies in the bloc. It set a May 21 deadline for Meta to respond.
Meta rejected NOYB's arguments, saying its approach complies with guidance from the European Data Protection Board and follows discussions with the Irish privacy enforcer. "NOYB's arguments are wrong on the facts and the law," a Meta spokesperson said.
"We've provided EU users with a clear way to object to their data being used for training AI at Meta, notifying them via email and in-app notifications that they can object at any time."
NOYB, which last year urged EU privacy enforcers to act, said Meta could give users an option to opt-in rather than opt-out and also provide clear conditions for AI training, such as using anonymised user data, in line with EU privacy rules.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
33 minutes ago
- Mint
Trump wants cheaper drugs like Europe has. How it works.
President Donald Trump doesn't just want to bring down prescription drug prices for Americans. He wants European countries to raise them to make up the revenue that drugmakers would lose from his policy. Trump is proposing a so-called most-favored-nation pricing model, which would set U.S. drug prices at the lowest level in other wealthy countries. But the pharmaceutical industry isn't buying into tying drug prices in the U.S. to prices in Europe—at least not knowing the details of the president's proposal. More details about the government's pricing model could come this week. On May 12, Trump directed government health officials to benchmark drug prices to international standards within 30 days. The lobbying group PhRMA, with members including U.S. pharma giants Eli Lilly, Pfizer, Johnson & Johnson, and AbbVie, has argued there are two reasons why U.S. drug prices are high: foreign countries not paying 'their fair share" for medicines, and middlemen such as pharmacy-benefit managers. Today, U.S. drug pricing is largely market driven. It involves negotiations between drug manufacturers, pharmacy-benefit managers, healthcare insurers and providers. European countries do it much differently. Each has its own way of determining drug prices, but most follow one of two broad approaches. The first approach, which Germany and France use, considers the overall clinical effectiveness of a new medicine. How does the new treatment compare to existing ones? Does it have added therapeutic benefits? If the new drug is substantially better, its price would reflect that. A second approach, used by the U.K., the Netherlands, and Sweden, analyzes cost effectiveness. This model not only compares the new drug to existing ones but also assesses the incremental value that the medicine brings to the health system. After the assessments, negotiations between drugmakers and the countries begin. Because many European countries have national health systems, they are in a strong negotiation position. If government negotiators think a medicine is too expensive for its effectiveness, they won't recommend its use. How Trump's MFN policy would work in practice isn't clear. Drug prices would probably be based on list prices in Europe since the prices paid by national health systems, or net prices, are confidential. The president's open-ended directive, laid out in an executive order, has many wondering how the U.S. could raise prices in Europe. Trump has made clear he wants to close the gap between U.S. and international prices, and has suggested he would use tariffs and export controls to achieve his goal. In theory, drugmakers could set list prices higher in Europe as long as it doesn't affect net prices, health policy expert Dr. Huseyin Naci told Barron's. In the U.K., for example, a higher list price could still lower the prices in other European countries. 'So that would still not be an acceptable approach to many other European countries," said Naci, who is associate professor of health policy at the London School of Economics. Overhauling Europe's decades-old pricing approaches would require fundamental changes to their pricing regulations—and there will be 'little appetite or ability" to alter them, Naci added. Cost is another complicating factor. 'Pharmaceutical spending is already one of the top categories of spending in many countries in terms of healthcare expenditure, so there's little room to accommodate higher prices and spending for pharmaceuticals in Europe," according to Naci. How Trump is planning to make Europeans pay more for drugs is the big question. He could use tariffs and trade negotiations as leverage. In early April, the president said a 'major" tax on pharmaceutical imports is coming 'very shortly," however nothing has been announced yet. In a trade agreement with the U.K. a month later, there is a provision on pharmaceuticals that states the U.K. will 'endeavor to improve the overall environment for pharmaceutical companies." What that means in practice still isn't clear. Write to Elsa Ohlen at
&w=3840&q=100)
Business Standard
35 minutes ago
- Business Standard
Meta brings AI video editing feature to Meta AI, Edits app: What's new
Meta has launched a new generative AI-based video editing tool within its Meta AI app that enables users to stylise short-form videos using a variety of preset prompts. According to the company, these prompts allow Meta AI to modify elements such as outfits, backgrounds, and overall visual style. The feature is also integrated into Meta's Edits app. Meta AI's video editing feature is currently limited to select regions including the US, but is expected to expand to more regions soon. The company also noted that the tool currently supports video clips up to 10 seconds long and is being offered for free for a limited time. Meta AI's video editing feature: What it offers Meta described the AI-powered video editor as simple and accessible, requiring no prior video-editing skills. Users can upload a clip to the Meta AI app, the Meta AI website, or the Edits app, then choose from over 50 preset prompts. Once a selection is made, Meta AI automatically modifies the video based on the chosen theme. Examples shared by Meta include turning clips into a 'graphic novel' style, transforming subjects into vintage comic illustrations, altering gloomy weather footage to add a dreamy aesthetic, or converting scenes into a video game environment complete with neon effects and battle attire. Videos edited through the Meta AI or Edits apps can be posted directly to Facebook and Instagram. Additionally, the Meta AI app and website allow sharing to Meta AI's Discover Feed. The feature is based on Meta's Movie Gen models and was built in partnership with creators to identify prompts that resonate with their audiences. While only preset prompts are supported at the moment, Meta said that custom text prompts will be available in a future update.
Time of India
37 minutes ago
- Time of India
India open to mutually beneficial arrangements on QCOs with trusted partners: Goyal
Live Events (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel India is open to mutually beneficial arrangements on implementing norms related quality standards with its trusted trading partners, Commerce and Industry Minister Piyush Goyal said on said India is implementing QCOs ( quality control orders ) to promote manufacturing of quality goods in the rules, standards, and process are the same for domestic as well imported goods and India does not discriminate between domestic manufacturers and foreign suppliers, he said, adding that equal treatment is given to companies of all the countries."But certainly there could be room to find innovative solutions so that it becomes easier for trusted partners who are producing good quality products to get pathways by which such approvals can become simpler."We are open to suggestions. We are in dialogue with several nations on a mutual benefit basis and a mutual recognition basis, if other nations are willing to respect the high quality goods that India makes and allow us to do our own certification process. We are happy to allow our trusted partners to do the same," Goyal he added that all such relationships will be based on mutual respect for each other's US and the EU, among others, have raised issues pertaining to these QCOs. The EU has sought simpler certification processes under these are designed to prevent the import of substandard goods and ensure consumer access to high-quality number of products under QCO coverage has witnessed a significant jump from 106 in 2014 to over 732 products by October move aligns with India's broader strategy to enhance domestic manufacturing standards while curbing the influx of low-quality imports.
